Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 137, 522-9

Controlled Trial of Sulpiride in Chronic Schizophrenic Patients

Clinical Trial

Controlled Trial of Sulpiride in Chronic Schizophrenic Patients

J G Edwards et al. Br J Psychiatry.

Abstract

In a double-blind comparative trial of sulpiride (600-1,800 mg/day) and trifluoperazine (15-45 mg/day) in 38 chronic schizophrenic patients, ratings of therapeutic results and unwanted effects were made at two-weekly interviews during the six weeks treatment period. The results show that sulpiride has neuroleptic properties and a spectrum of therapeutic activity similar to that of trifluoperazine. There was an association between plasma sulpiride levels and therapeutic response after four weeks' treatment.

Similar articles

See all similar articles

Cited by 9 PubMed Central articles

See all "Cited by" articles

LinkOut - more resources

Feedback